Quark and Suzhou Ribo Start China Trial of Anti-Blindness RNAi Drug

Quark Pharma, a US-Israeli developer of RNA-interference drugs, has begun a global Phase II/III trial of its siRNA treatment for blindness, including a China arm. Two years ago, Quark established a China JV with Suzhou Ribo Life Science to develop the drug in China, funded with $7.5 million in venture capital. Quark said the approval is the first in China for an RNAi drug. QPI-1007 seeks to prevent deterioration of the optic nerve, a condition known as non-arteritic anterior ischemic optic neuropathy (NAION). More details.... Share this with colleagues: // //